Welcome. If you're a registered user, please log-in. If not, please sign-up.
Two Conferences, 1 price

Workshops

4 Brand NEW Workshops

Pre-Conference Workshop (X): Tuesday 20 May 2014

Update and Best Strategies for Accessing the US Market for Biosimilars

Registration is at 08:30 for a 09:00 start. The workshop will finish no later than 16:00. Workshop documents, refreshments and lunch will be provided.

 

Update on progress of US biosimilar guidelines and beyond

  • What is the current status of FDA biosimilar guidelines and likely timelines for finalisation?
  • Using the FDA biosimilar guidelines as a competitive tool
  • Commercial barriers beyond FDA biosimilar guidelines
  • INN naming: An alternative way of looking at this hot topic
  • How will approaches to biosimilars vary between different US states vs. federal agency FDA and what is the impact on the fate of biosimilars?
  • To what degree will FDA follow suit of the EMA regarding approval of biosimilars? Compare US and Europe, how are they aligning?
  • Coordination between authorities - joint EMA-FDA informal scientific advice: How is it working?
  • I have a dream: One application for several authorities; is it possible in 2014?
  • Best strategies to avoid the 351k pathway and still be reimbursed by payers with physician and patients’ acceptance

Industry insight

  • EU/US Regulatory Landscape- common concepts
  • -EU overview
  • -US Overview
  • Global harmonisation challenges
  • Regulatory Agency advice - common concepts and needs for biosimilars
  • US BsUFA
  • CHMP Scientific Advice Overview
  • Considerations for an integrated approach
  • Case Study Parallel EMA and FDA advice

Workshop leaders:

Shivanthy Visvalingam DPhil, Manager EU Regulatory Strategy for Biosimilars, Pfizer, UK

Michel Mikhail, Chief Regulatory Officer, Executive Vice President, Global Regulatory – Governmental Relations, Fresenius Kabi, Germany

Richard Dicicco, Chairman, Harvest Moon Pharmaceuticals, USA

 

Pre-Conference Workshop (Y): Tuesday 20 May 2014

Practically Developing and Validating Immunogenicity Assays for Biosimilar Drug Development

Registration is at 08:30 for a 09:00 start. The workshop will finish no later than 16:00. Workshop documents, refreshments and lunch will be provided.

Regulatory agencies require that immunogenicity be evaluated in comparative studies between biosimilar and originator drugs and it is essential that your assays are optimal. This workshop will discuss methods for developing and validating immunogenicity assays to support preclinical and clinical comparative studies for biosimilar drug development

Immunogenicity testing for biosimilars: How to translate regulatory expectations into clinical studies

  • Immunogenicity testing for biosimilars: Regulatory framework 
  • Susceptibility of the immunogenicity towards comparability and compatibility issues 
  • Design aspects of immunogenicity studies: Eligible population, duration and power 
  • Dealing with improved immunogenicity profiles 
  • Interferon ß: A first attempt to harmonize immunogenicity testing across companies 
  • Non-comparative post-marketing surveillance of immunogenicity 

Dr Bernd Liedert, Director, Head of Immunopharmacology Onc., Merck Serono, Germany

 

Preclinical Immunogenicity Assessment of PEGylated protein therapeutics

  • Challenges for pre-clinical immunogenicity assessment of protein therapeutics
  • Strategies for preclinical immunogenicity assessment
  • New mouse models for comparative immunogenicity assessments
  • PEG- modification of protein therapeutics:  risk or benefit for immunogenicity?
  • Case study: preclinical immunogenicity assessment of a PEGylated recombinant coagulation factor

Dr Frank Horling, Senior Manager, Immunology, Biologics R&D, Baxter, USA

 

Immunogenicity testing for comparibility reasons: the do’s and don’ts

Philippe Stas, Chief Executive Officer, BLA Consult bvba, Belgium

 

Additional topics to be addressed:

  • Regulatory requirements and expectations for immunogenicity assays
  • How have successful immunogenicity methods been developed and validated?
  • How to ensure that your assay is specific enough to measure any differences between biosimilar and original product?

Michael G Tovey, INSERM Director of Research, Laboratory of Biotechnology and Applied Pharmacology, ENS-Cachan, France 

Sofie Pattijn, Consultant, Belgium

Arno Kromminga, CEO/CSO, IPM Biotech, Germany

 

Evening Seminar (S): Wednesday 21 May 2014

Regulatory Professionals Evening Surgery

Registration is at 18:00 for an 18:15 start. The seminar will finish no later than 20:30. Seminar documents and an evening networking dinner will be provided.

This highly interactive seminar will provide regulatory feedback on key regulatory hurdles encountered by industry. This will be followed with time for open Q&A so that specific individual issues can be discussed.

 

  • How similar is similar? What is likely not to be accepted by the regulator?
  • Comparability studies: Regulatory guidance on how to practically carry out comparability studies and prove comparability to the regulator?
  • Immunogenicity: How should immunogenicity be reported? How can key concerns and risk be measured and effectively addressed?
  • Extrapolation of indications: How do regulators justify doing extrapolation?
  • How do the regulators handle biosimilar applications from industry and what is the experience here?
  • What is the regulatory advice on a stepwise approach for achieving approval, including the analytical package and clinical testing?

 

The above topics will form the main focus of the seminar, however there will be opportunity to discuss other issues and ask specific questions.

 

Workshop leaders:

Dr Gabriele Reichmann, Scientific Assessor, Paul-Ehrlich-Institute, Germany

Roman Ivanov, Vice President, Research & Development, BIOCAD, Russia

Daotian Fu, Executive VP, Livzon Mabpharm, Inc., China

 

Post-Conference Workshop (Z): Friday 23 May 2014

Practically Conducting Clinical Development of Biosimilars and Complying with Regulatory Expectations

Registration is at 08.30 for a 09.00 start. The workshop will finish no later than 16.00. Workshop documents, refreshments and lunch will be provided.

 

  • Clinical development of Biosimilars versus Generics and novel Biopharmaceuticals
  • Designing single global clinical trials for US and EU
  • Practical considerations of originator sourcing
  • Practical considerations for designing biosimilars clinical studies, including:
  • Study size – is there scope to reduce the size of clinical trial?
  • Endpoints
  • How much data is required?
  • What is the best way to present data to the regulators?
  • How do you carry out effective comparative analysis of clinical data and ensure this comparison is fair?
  • Can clinical trials be used to prove interchangeability and how can this be carried out?
  • Are pharmacodynamics studies ever acceptable to show biosimilarity when indications are not approved?
  • How can clinical study costs be effectively controlled and kept to a minimum?
  • Determination of the relative immunogenicity of innovator products and biosimilars during clinical development.

Workshop leaders :

Carsten Brockmeyer, CEO, Formycon, AG, Germany

Michael G Tovey, INSERM Director of Research, Laboratory of Biotechnology and Applied Pharmacology, ENS-Cachan, France

Philippe Stas, Chief Executive Officer, BLA Consult bvba, Belgium



Choose your language

Japanese  
Korean  
Chinese Traditional Chinese Traditional
Chinese Simplified Chinese Simplified

LinkedIN

Join the Biopharmaceutical Professionals Europe group on LinkedIn for your chance to discuss this topic with experts in the field, and also keep updated with the latest news on the conference.

Click Here and request to join the group!

Poll

Who will be the first to have a Biosimilar approved in the US?